Charles University Team Uses Laser Microscopy to Uncover Schistosome Egg Secrets

A research group at the Faculty of Science, Charles University, has announced a breakthrough in the fight against schistosomiasis by isolating and analyzing individual parasite eggs with laser‑assisted microdissection, revealing previously hidden molecular features that could become targets for new interventions.

Schistosomiasis, a water‑borne disease caused by flatworms of the genus Schistosoma, afflicts more than 250 million people worldwide, predominantly in tropical and subtropical regions. The disease’s morbidity stems largely from the eggs the parasites deposit in host tissues, where they trigger chronic inflammation and organ damage.

The Czech team employed a high‑precision laser to cut out single eggs from infected tissue samples, a technique that preserves the integrity of the minute structures while allowing detailed biochemical profiling. This approach bypasses the need for bulk tissue grinding, which can mask differences between egg populations.

Analysis of the isolated eggs revealed distinct protein signatures that vary between developmental stages and even between species of Schistosoma. Some of these proteins appear to function as “secret weapons,” helping the eggs evade the host’s immune response and facilitating their migration through blood vessels.

These findings are significant because they point to concrete molecular candidates for vaccines or diagnostic tests. Current treatment relies heavily on a single drug, praziquantel, and emerging resistance underscores the urgency of diversifying therapeutic options.

Experts note that the study underscores the value of precision‑level techniques in parasitology, a field where many pathogens are still examined only in bulk. By pinpointing the exact components that make eggs pathogenic, researchers can design interventions that interrupt the disease cycle at its most damaging stage.

The Charles University scientists plan to validate the identified proteins in animal models and collaborate with international health agencies to explore their potential in vaccine development. If successful, the work could reshape strategies for controlling a disease that remains a leading cause of disability in many low‑income countries.